中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

70 records (took 0.034 seconds)

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    41.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号：KR1020080007329A

    公开(公告)日：2008-01-18

    申请号：KR1020077024002

    申请日：2006-03-15

    Applicant: (주)아모레퍼시픽

    Inventor： 김희두 ,  서영거 ,  박형근 ,  오우택 ,  박설린 ,  김주현 ,  장미정 ,  박영호 ,  신송석 ,  김선영 ,  김진관 ,  정연수 ,  이기화 ,  최진규 ,  임경민 ,  고현주 ,  모주현 ,  김성일 ,  우병영

    IPC: C07C275/24 ,  C07C275/18 ,  A61K31/17

    CPC classification number: C07C275/24 ,  C07C311/08 ,  C07C311/11 ,  C07C323/62 ,  C07D211/46 ,  C07D295/088 ,  C07D295/155 ,  C07D309/12 ,  C07F7/0818

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.

    Abstract translation: 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛，偏头痛，关节痛，神经损伤，皮肤疾病，膀胱过度活动症，肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物，其异构体或其药学上可接受的盐由下式I表示。在式I中，X为NHCH 2，CR 11 = CR 12，NH，CHR 11 CHR 12或C = C，其中R 11和R 12 表示H，卤素，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基或C2-C5炔基; R2是H，卤素，硝基，氰基，C1-C5烷基，C1-C5烷氧基，卤代（C1-C5）烷基，C2-C5烯基，C2-C5炔基，羧基，C1-C5烷氧羰基，C1-C5烷硫基， 苯基或苯基（C1-C3）烷基，其中每个苯基是未取代的或被至少一个取代基取代; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R 4，R 5，R 6，R 7和R 8各自独立地表示H，羧基，C 1 -C 5烷基，硝基，C 2 -C 5烯基，C 1 -C 5烷氧基，C 2 -C 5炔基，卤代（C 1 -C 5）烷基，C 1 -C 5烷硫基 ，C1-C5烷基磺酰基，C1-C5烷基羰基，C1-C5烷氧基羰基，羟基，C2-C5链烯氧基，C1-C5烷氧基（C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷氧基（C1-C5）烷基 （C1-C5）烷氧基，C1-C5烷氧基（C1-C5）烷基氨基，C1-C7烷基氨基，吗啉基，吗啉基（C1-C5）烷氧基，四氢吡喃基氧基， 苯基或卤素，其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H，-SO 2 R 13，-SOR 13，C 1 -C 5烷基，C 1 -C 5烷氧基，卤代（C 1 -C 5）烷基，C 2 -C 5烯基，C 1 -C 5烷氧基羰基，C 1 -C 5烷硫基，苯基或 苯基（C1-C3）烷基，其中每个苯基未被取代或被至少一个取代基取代，R 13是H，氨基，C 1 -C 5烷基，C 2 -C 5烯基，C 1 -C 5烷氧基，卤代（C1- C5）烷基，三氟甲基，苯基或苯基（C1-C3）烷基。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    42.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号：KR1020070114821A

    公开(公告)日：2007-12-04

    申请号：KR1020077024004

    申请日：2006-03-17

    Applicant: (주)아모레퍼시픽

    Inventor： 서영거 ,  김희두 ,  박형근 ,  오우택 ,  이용실 ,  박설린 ,  유정현 ,  박영호 ,  신송석 ,  김선영 ,  김진관 ,  정연수 ,  이기화 ,  최진규 ,  임경민 ,  고현주 ,  모주현 ,  김성일 ,  배준호

    IPC: C07C275/24 ,  C07C275/18 ,  A61K31/17

    CPC classification number: C07C275/24 ,  C07C311/08 ,  C07C311/11 ,  C07C323/62 ,  C07D211/46 ,  C07D295/088 ,  C07D295/155 ,  C07D309/12 ,  C07F7/0818

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a high activity in preventing or treating pain, migraine, arthralgia, neuralgia, neural diseases, neural injury, skin diseases, irritable bowel syndrome, inflammatory diseases, cardiac diseases, etc. A compound as a vanilloid receptor antagonist is a compound represented by the following formula Ia or an isomer and/or pharmaceutically acceptable salt thereof. In formula Ia, X is CR11=CR12 or C=C, wherein each of R11 and R12 independently represents H, a halogen atom, C1-C5 alkyl or phenyl; each of R1 and R2 independently represents H, carboxyl, C1-C5 alkyl, halogen, nitro, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylsulfonylamino, phenylsulfonylamino, C1-C5 alkylthio, C1-C5 alkylsulfonyl or C1-C5 alkoxycarbonyl; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5, R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, phenyl or halogen, wherein the phenyl is non-substituted or substituted with at least one substituent selected from carboxyl, C1-C5 alkyl, halogen, nitro, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl and C1-C5 alkoxycarbonyl; R9 is C1-C5 alkylsulfonyl or C2-C5 alkenylsulfonyl; and R10 is H, with the proviso that when R3 is not H, R11 and R13 cannot represent H at the same time.

    Abstract translation: 提供了一种作为香草素受体拮抗剂的化合物，用于预防或治疗疼痛，偏头痛，关节痛，神经痛，神经疾病，神经损伤，皮肤病，肠易激综合征，炎性疾病，心脏病等中的高活性。 香草酸受体拮抗剂是由下式Ia表示的化合物或其异构体和/或其药学上可接受的盐。 在式Ia中，X是CR 11 = CR 12或C = C，其中R 11和R 12各自独立地表示H，卤素原子，C 1 -C 5烷基或苯基; R1和R2各自独立地表示H，羧基，C1-C5烷基，卤素，硝基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷基羰基氨基，C1-C5烷基磺酰基氨基，苯基磺酰基氨基， C1-C5烷硫基，C1-C5烷基磺酰基或C1-C5烷氧基羰基; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R4，R5，R6，R7和R8各自独立地表示H，羧基，C1-C5烷基，硝基，C2-C5烯基，C1-C5烷氧基，C2-C5炔基，卤代（C1-C5）烷基，C1-C5 烷基硫代，C 1 -C 5烷基磺酰基，C 1 -C 5烷基羰基，C 1 -C 5烷氧基羰基，苯基或卤素，其中苯基是未取代的或被至少一个选自羧基，C 1 -C 5烷基，卤素，硝基， C5链烯基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷硫基，C1-C5烷基磺酰基和C1-C5烷氧基羰基; R9为C1-C5烷基磺酰基或C2-C5链烯基磺酰基; R 10为H，条件是当R3不为H时，R11和R13不能同时表示H。

    유색콩 추출물을 함유하는 조성물
    46.
    发明公开
    유색콩 추출물을 함유하는 조성물 无效
    包含色素提取物的组合物

    公开(公告)号：KR1020160073950A

    公开(公告)日：2016-06-27

    申请号：KR1020160071842

    申请日：2016-06-09

    Applicant: (주)아모레퍼시픽

    Inventor： 김진관 ,  김채욱 ,  정연수 ,  윤준원 ,  임경민 ,  주영협 ,  박영호 ,  신현정

    IPC: A61K36/48 ,  A23L1/30

    CPC classification number: A61K36/48 ,  A23L33/105 ,  A23V2200/30 ,  A23V2200/326

    Abstract: 본발명은유색콩등으로부터추출한유색콩추출물및 그분획물을유효성분으로함유하는항혈전효능조성물에관한것이다. 본발명에의한항혈전조성물은아데노신을포함하고있으며, 혈전형성의원인이되는심장혈관질환, 뇌혈관질환, 동맥경화증, 고혈압, 당뇨등의순환기계질환의치료에매우유용하게이용될수 있다.

    Abstract translation: 本发明涉及抗紫外线组合物，其含有作为活性成分的从有色豆及其部分提取的有色豆提取物。 本发明的抗血栓形成组合物含有腺苷，可用于治疗血栓形成原因的心血管疾病，脑血管疾病，动脉粥样硬化，高血压，糖尿病等循环系统疾病。

    카나비노이드 1 수용체 저해제로 작용하는 신규 화합물
    47.
    发明公开
    카나비노이드 1 수용체 저해제로 작용하는 신규 화합물 审中-实审
    新型化合物作为CANNABINOID受体-1抑制剂

    公开(公告)号：KR1020130099930A

    公开(公告)日：2013-09-06

    申请号：KR1020137005744

    申请日：2011-08-31

    Applicant: (주)아모레퍼시픽

    Inventor： 신송석 ,  홍용덕 ,  변경희 ,  박미영 ,  최진규 ,  박양희 ,  배일홍 ,  주영협 ,  임경민 ,  박영호

    IPC: C07D487/04 ,  C07D403/04 ,  A61K31/519 ,  A61P29/00

    CPC classification number: C07D487/04 ,  A61K31/519

    Abstract: PURPOSE: A novel compound is provided to prevent or treat diseases mediated by a cannabinoid 1 receptor. CONSTITUTION: A compound of chemical formula 1 or a prodrug, an isomer, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof is provided. A pharmaceutical composition contains the compound of chemical formula 1, the prodrug, the isomer, the pharmaceutically acceptable salt, the hydrate, or the solvate thereof. The pharmaceutical composition is used for preventing or treating diseases mediated by cannabinoid 1 receptor. The diseases medicated by cannabinoid 1 receptor are obesity.

    Abstract translation: 目的：提供一种新型化合物，用于预防或治疗由大麻素1受体介导的疾病。 构成：提供化学式1化合物或其前体药物，异构体，药学上可接受的盐，水合物或溶剂合物。 药物组合物含有化学式1的化合物，前药，异构体，药学上可接受的盐，水合物或其溶剂化物。 药物组合物用于预防或治疗由大麻素1受体介导的疾病。 由大麻素1受体引起的疾病是肥胖。

    피부 노화 방지용 조성물
    50.
    发明授权
    피부 노화 방지용 조성물 有权
    预防皮肤老化的组合物

    公开(公告)号：KR101252335B1

    公开(公告)日：2013-04-08

    申请号：KR1020090065107

    申请日：2009-07-16

    Applicant: (주)아모레퍼시픽

    Inventor： 백흥수 ,  김선영 ,  우병영 ,  나용주 ,  박녹현 ,  이지해 ,  김혁 ,  김연준 ,  남미희 ,  주영협 ,  임경민

    IPC: A61K8/49 ,  A61Q19/08 ,  A61K31/352 ,  A61P17/18

    Abstract: 본 발명은 하기 화학식 1의 화합물, 그것의 이성질체 또는 약제학적으로 허용 가능한 염을 유효 성분으로 포함하는 피부 노화 방지용 조성물에 관한 것이다.
    (화학식 1)

    본 발명에 따른 조성물에 포함되는 화학식 1의 화합물, 그것의 이성질체 또는 약제학적으로 허용 가능한 염은 피부 자극을 유발하지 않으면서, 신경 통증감각 수용체(TRPV1: Transient Receptor Potential family V 1) 길항제로 작용하여, 매트릭스 메탈로프로티아제(matrix metalloprotease) 활성 억제 효과를 발휘하는 바, 피부 노화 방지용 조성물의 유효 성분으로 적합하게 사용될 수 있다.
    피부 노화 방지

Patent Agency Ranking